Camargo Pharmaceutical Services
10151 Carver Road
49 articles with Camargo Pharmaceutical Services
Camargo Pharmaceutical Services, LLC, a global drug development and commercial partner, announced today the appointment of Reeves McGee as Chief Commercial Officer. In this senior leadership role, McGee will oversee the development and implementation of Camargo's commercial strategies, its commercial organic growth initiatives and the
Camargo Pharmaceutical Services, LLC, a global drug development and commercial partner, announced the appointment of Jennie Orr as Chief Strategy and Business Officer.
Robb Lawrence Appointed Vice President of Commercial Strategy at Camargo Pharmaceutical Services, LLC
Camargo Pharmaceutical Services, LLC, a global drug development and commercial partner, announced today the appointment of Robb Lawrence as Vice President of Commercial Strategy. In this senior leadership role, Lawrence will lead the design and development of strategic solutions that optimize patient access and outcomes by navigating the
Camargo client Chiasma receives FDA approval for first and only oral somatostatin analog for long-term maintenance treatment of acromegaly
Camargo Pharmaceutical Services, LLC, congratulates Chiasma, Inc. on obtaining approval from the US Food and Drug Administration for MYCAPSSA® (octreotide) capsules. MYCAPSSA is the first and only oral somatostatin analog (SSA) approved by the FDA.
Camargo Pharmaceutical Services Enhances Drug Development Services Through Acquisition of Montreal-based InSymbiosis
Acquisition strengthens integrated drug development solution and expands global footprint
Cellix Biosciences Inc. today announced successful completion of a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA).
Camargo Congratulates US WorldMeds on Obtaining FDA Approval for the First Non-Opioid Medicine for the Management of Opioid Withdrawal Symptoms
Camargo Pharmaceutical Services, LLC congratulates US WorldMeds, LLC, on obtaining US Food and Drug Administration (FDA) approval for LUCEMYRA™ (lofexidine) tablets
June 1, 2018 marks the 15th anniversary for Camargo Pharmaceutical Services, LLC, ("Camargo").
Camargo Pharmaceutical Services, LLC, announced the appointment of Daniel S. Duffy as new Chief Executive Officer.
V ClinBio Partners with Camargo for Strategic 505(b)(2) Development of Transformative Prodrug Technology Platform
Camargo will provide end-to-end regulatory consulting and strategic development services.
Medicines360 and Camargo Pharmaceutical Services Gain FDA Approval for Intrauterine Contraceptive Device
Camargo Pharmaceutical Services And FDA To Share 505(b)(2) Expertise At 2015 American Association of Pharmaceutical Scientists Annual Meeting And Exposition
Camargo Pharmaceutical Services Adds Extensive Scientific, Regulatory And Legal Affairs Experience To Team